How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more ...
In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...
Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...
The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact ...
Phase IIIb SURMOUNT-Maintain showed near-complete weight-loss maintenance on maximum tolerated tirzepatide through Week 112, while a 5 mg step-down dose was associated with 5.6 kg mean regain.
Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...
Robert F. Kennedy reportedly initiated Makary’s ouster, and the White House signed off, underscoring HHS-driven influence over FDA leadership and the agency’s near-term policy direction. Kyle ...
In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ ...
Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how ...
An exclusive China launch collaboration positions CTTQ to lead importation, distribution, hospital access, and promotion, while GSK retains marketing authorization and oversight of regulatory, quality ...
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results